Recruiting
Phase 1
Phase 2

AM3101

Sponsor:

University of Cincinnati

Code:

NCT05560477

Conditions

Meniscus Tear

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Not accepted

Interventions

AM3101

Saline Placebo

Study Details

Brief summary:

The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.

Conditions

Meniscus Tear

Study ID

NCT05560477

Start date

Apr 26, 2023

Status verified date

May, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female ≥ 18 and ≤ 40 years old at time of screening.
2. MRI evidence of ACL plus meniscus tear, or isolated meniscus tear.
3. Body mass index (BMI) ≤ 40 kg/m2.
4. Liver and kidney function panels within normal ranges at time of screening
5. Willing and able to comply with the study procedures and visit schedule, and able to follow oral and written instructions.
6. Willing and able to sign an IRB approved informed consent

Exclusion Criteria:

1. Have any concomitant ligament injury requiring surgical repair or reconstruction other than the ACL.
2. Have a history of previous meniscus injury that currently needs to be treated or has been treated surgically.
3. Have evidence of arthritis ≥ Grade III (Outerbridge classification) in the affected compartment or greater than Kellgren Lawrence Grade 3.
4. Elevated AST or ALT liver enzymes at time of screening
5. Pregnant or nursing mothers, or women planning on getting pregnant during the time they will be participating in the study.
6. Known drug or alcohol dependence currently or within the last year.
7. Participating concurrently in another clinical study or have participated in a clinical study within the last 90 days, or intend to during the course of the study.
8. Any medical condition or other circumstances that might interfere with the ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate postoperative rehabilitation.
9. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the investigational product's safety and efficacy.
10. Known allergic reaction to simvastatin.
11. Patients currently taking simvastatin, or any other drug that is within the statin drug classification family.

Study Design

Enrollment

74 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treated with repair and AM3101

Syringe containing AM3101 for injection.

placebo comparator: Treated with repair and 0.9% sodium chloride (saline)

Syringe containing commercially available 0.9% sodium chloride for injection.

Interventions

AM3101

Injectable drug product.

Saline Placebo

2 mL 0.9% normal saline

Primary outcome measure

  • Healing Assessed via MRI [ Time Frame: 12 months ]
  • Incidence of Adverse Events [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

Principal Investigator:

Brian M Grawe, MD

University Hospitals Cleveland Medical Center

Recruiting

Cleveland, Ohio, United States, 44106

Contacts

Principal Investigator:

Jacob Calcei, MD

Oregon Health & Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Principal Investigator:

Jacqueline Brady, MD

More Information

Sponsor

University of Cincinnati

Last update posted

May 4, 2026

Last verified

May, 2025

Keywords

  • meniscal repair
  • complications
  • morbidities

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Cincinnati on 2026-05-04.